Monitoring and reversal strategies for new oral anticoagulants

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran (thrombin inhibitor) and factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).
• NOACs are effective and safe alternatives to warfarin for venous thromboembolism and atrial fibrillation, without requiring routine monitoring.
• Currently, no validated reversal strategies exist for NOAC-associated bleeding events.

Purpose of the Study:

• To review laboratory assays for measuring NOACs and managing associated hemorrhages.
• To compare the utility of routine coagulation tests versus specific laboratory assays.
• To summarize prohemostatic measures and recommended bleeding management strategies.

Main Methods:

• Literature review comparing routine coagulation tests and specific laboratory assays.
• Review of prohemostatic measures.
• Summary of recommended strategies for NOAC-induced bleeding.

Main Results:

• Routine coagulation tests have limitations in accurately assessing NOAC levels.
• Specific laboratory assays offer better drug measurement but require further validation.
• Prohemostatic measures and management strategies are being developed, with specific reversal agents in trials.

Conclusions:

• Effective management of NOAC-associated bleeding requires improved laboratory diagnostics and validated reversal strategies.
• Specific reversal agents like idarucizumab, andexanet alfa, and PER977 show promise for clinical application.
• These advancements are critical for managing severe bleeding and facilitating emergency procedures in patients on NOACs.